期刊文献+

二膦酸盐相关性颌骨坏死研究进展 被引量:3

下载PDF
导出
摘要 二膦酸盐类药物是临床上重要的抗骨吸收药物之一,作用机理在于能够特异性的与骨质中羟磷灰石结合,破坏破骨细胞活性,从而抑制骨吸收,临床应用包括治疗代谢性骨疾病、骨质疏松症、肿瘤骨转移以及关节成形术后骨溶解并发症等[1]。2003年Marx首次报道该药物应用导致颌骨坏死并发症[2],引起国内外学者广泛重视,并对该并发症进行了深入研究,本文回顾近几年研究现状,综述如下。
出处 《口腔医学研究》 CAS CSCD 2012年第11期1197-1199,1202,共4页 Journal of Oral Science Research
  • 相关文献

参考文献6

  • 1Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and time to osteonecrosis development [J]. Oncologist, 2009, 14 (11) : 1154-1166.
  • 2Kassolis JD, Scheper M, Jham B, et al. Histopathologic findings in bone from edentulous alveolar ridges: a role in os- teoneerosis of the jaws [J]? Bone, 2010, 47(1) : 127-130.
  • 3Russell RG. Bisphosphonates: The first 40 years [J]. Bone, 2011, 49(1): 2-19.
  • 4Wen D, Qing L, Harrison G, ctal. Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate[J]. Oral Dis, 2011, 17(4) : 427-432.
  • 5Van den Wyngaert T, Claeys T, Huizing MT, et al. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of out- come[J]. Ann Oncol, 2009, 20(2) : 331-336.
  • 6Stumpe MR, Chandra RK, Yunus F, et al. Incidence and risk factors of bisphosphonate - associated osteonecrosis of the jaws[J].Head Neck, 2009, 31(2) : 202-206.

同被引文献35

  • 1Pan Wei,Ming Liu,Yan Chen,De-Cai Chen.Systematic review of soy isoflavone supplements on osteoporosis in women[J].Asian Pacific Journal of Tropical Medicine,2012,5(3):243-248. 被引量:13
  • 2骆凯,闫福华,陈凌,郑碧琼,陈玉玲.绝经后骨质疏松大鼠实验性牙周炎动物模型研究[J].口腔医学研究,2006,22(2):130-132. 被引量:16
  • 3JAGTAP V R,GANU J V. Effect of antiresorptive therapy on urinary hydroxyproline in postmenopausal osteoporosis[J]. Indian J Clin Biochem,2012,27(1):90-93.
  • 4TOULIS K A, ANASTASILAKIS A D, POLYZOS S A. et al. Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis[J]. Hormones (Athens), 2011,10(3) : 174-195.
  • 5IOLASCON G,GIMIGLIANO F, MALAVOLTA N, et al. Effec tiveness of teriparatide treatment on back pain-related functional limitations in individuals affected by severe osteoporosis: a pro- spective pilot study[J]. Clin Cases Miner Bone Metab, 2012.9 (3) 161-165.
  • 6Burr D, Russell G. Foreword: bisphosphonates [J]. Bone, 2011, 49(1): 1.
  • 7Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic [J]. J Oral Maxillofac Surg, 2003, 61(9): 1115-1117.
  • 8Boonyapakorn T, Schirmer I, Reichart PA, et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies [J]. Oral Oncol, 2008, 44(9): 857-869.
  • 9Abu-Id MH, Warnke PH, Gottschalk J, et al. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw [J]. J Craniomaxillofac Surg, 2008, 36(2): 95-103.
  • 10Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update [J].J Oral Maxillofac Surg, 2009, 67(5 Suppl): 2-12.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部